Ten weeks of aerobic training does not result in persistent changes in VLDL triglyceride turnover or oxidation in healthy men

Birgitte Nellemann, Britt Christensen, Kristian Vissing1, Line Thams1, Peter Sieljacks1, Mads Sørensen Larsen1, Jens Otto Lunde Jørgensen and Søren Nielsen

Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Norrebrogade 44, 8000 Aarhus C, Denmark and 1Section of Sports Science, Department of Public Health, Aarhus University, Aarhus, Denmark

Abstract

Objective: Very low density lipoprotein triglyceride (VLDL–TG) and free fatty acids (FFA) constitute a substantial proportion of human energy supply both at rest and during exercise. Exercise acutely decreases VLDL–TG concentration, and VLDL–TG clearance is increased after an exercise bout. However, the effects of long-term training are not clear.

Design: The aim was to investigate long-term effects of training by direct assessments of VLDL–TG and palmitate kinetics and oxidation in healthy lean men (n = 9) at rest, before and after a 10-week training program, compared with a non-training control group (n = 9).

Methods: VLDL–TG kinetics were assessed by a primed constant infusion of [1-14C]VLDL–TG, and VLDL–TG oxidation by specific activity (14CO2) in expired air. The metabolic study days were placed 60–72 h after the last exercise bout.

Results: Palmitate kinetics and oxidation were assessed by a 2 h constant infusion of [9,10-3H]palmitate. In the training group (n = 9), maximal oxygen uptake increased significantly by ~20% (P < 0.05), and the insulin sensitivity (assessed by the hyperinsulinemic–euglycemic clamp) improved significantly (P < 0.05). Despite these metabolic improvements, no changes were observed in VLDL–TG secretion, clearance, or oxidation or in palmitate kinetics.

Conclusion: We conclude that 10 weeks of exercise training did not induce changes in VLDL–TG and palmitate kinetics in healthy lean men.
metabolism are plausible. Animal studies indicate that long-term endurance training is associated with decreased hepatic VLDL–TG secretion (13, 14, 15). Human studies, however, show somewhat divergent results. Long-term training has shown both decreased and unchanged VLDL–TG levels (16, 17), but whether the reduction (16) was due to reduced hepatic secretion or increased peripheral clearance of VLDL–TG is not clear. On the other hand, 6 months of supervised endurance training was associated with decreased apoB-100 secretion, a measure of VLDL particle number, examined by [1-13C]leucine tracer (18). This method, however, does not provide information regarding either TG content of the VLDL particles or VLDL–TG FA oxidation. Other kinetic studies using glycerol precursor labeling of VLDL–TG in combination with mathematical modeling have found both decreased (19) and unaltered (20) hepatic VLDL–TG secretion rates following training programs. The differences between these and the present studies may be due to differences in the intensity and duration of the training programs as well as in the volunteers studied. Importantly, however, the methods used do not allow direct measurements of VLDL–TG FA oxidation, which is central to understanding the mechanisms underlying prolonged effects of training on systemic VLDL–TG metabolism.

Previous studies have reported (21, 22, 23) that postabsorptive VLDL–TG FA accounts for 10–15% of whole-body resting energy expenditure (REE) in healthy sedentary humans (22, 23, 24). Moreover, VLDL–TG secretion and clearance rates were significantly decreased during acute exercise as well as during the immediate recovery of the exercise bout of 90 min at 50% of maximal oxygen uptake (VO2max), whereas VLDL–TG FA oxidation rate was largely unchanged compared with resting levels (22).

Exercise also improves insulin sensitivity directly for about 48 h after an exercise bout (25, 26), and insulin modulates hepatic VLDL–TG secretion. For example, insulin acutely suppresses hepatic VLDL–TG secretion, while insulin resistance is associated with increased hepatic VLDL–TG secretion rates both in the basal state and during insulin stimulation (27, 28). Therefore, we hypothesized that a persistent improvement in insulin sensitivity in response to a prolonged training intervention would also lead to sustained changes in VLDL–TG and palmitate kinetics. In this study, we investigated the impact of a 10-week training intervention in healthy, sedentary men on plasma VLDL–TG and FFA kinetics and oxidation using i.v. infusion of [1-14C]VLDL–TG and [9,10-3H]palmitate in combination with measurements of plasma isotopic specific activity (SA) and exhaled 14CO2 before and after the 10-week intervention period.

**Subjects and methods**

**Subjects**

Eighteen healthy young men were studied as part of a larger study involving training (Tr) intervention, erythropoiesis-stimulating agent (Darbepoetin alfa) treatment as compared with a physically inactive control (C) group. This study examined VLDL–TG and FFA (palmitate) kinetics and oxidation rates of the participants in the C and Tr subgroups with no injections of erythropoiesis-stimulating agent. Inclusion criteria (29) required that all participants were untrained, with a VO2max < 50 ml/kg per min. Additionally, all were normotensive, non-smokers, used no medication, and had a normal blood count, lipid profile, fasting plasma glucose, HbA1c, and a normal electrocardiogram. The study was registered on www.clinicaltrials.gov (NCT01320449). The Regional Scientific Ethics Committee of Central Denmark approved the study protocol (M-20110035), and written informed consent was obtained from all participants.

**Experimental design**

A detailed description of the study design has been reported elsewhere (29). In brief, in a randomized, paired design, subjects were allocated to a C group (n = 9) or a Tr group (n = 10). One participant in the Tr group was excluded from this study compared with the overall study due to incomplete data. Additionally, for two further participants in the Tr group, it was not possible to measure palmitate oxidation. VO2max was determined by an incremental cycling protocol (starting at 140 watt and 35 watt increase/min) until exhaustion on a stationary exercise bike (Monark, Ergomedic 828E, Varberg, Sweden) before inclusion and after the last study day in both groups. The Tr group participated in supervised endurance bicycle exercise thrice weekly for 10 weeks (30). The training protocol consisted of three different weekly exercise sessions. After a 5-min warm-up, one of three training sessions was performed: ‘Session 1’, 40 min; ‘Session 2’, 2 × 20 min; or ‘Session 3’, 8 × 5 min, thus comprising both high-intensity aerobic exercise and moderate-intensity endurance exercise. Sessions were performed at an average of 65% of watt-max. Lipid kinetic studies were carried out under resting conditions at baseline and after 10 weeks. In order to avoid any acute
effects of exercise, the post-training metabolic study day was scheduled 60–72 h after the last exercise bout. Moreover, the participants were instructed to abstain from other strenuous exercise and alcohol consumption 2 days before the metabolic study days, and not to change their diet for 3 days before each metabolic study day.

**Metabolic study day**

Participants fasted from 1000 h the evening before the study days (only tap or mineral water was allowed). In the morning, volunteers arrived by taxi, and were immediately admitted to the Research Unit and instructed to avoid unnecessary physical activity. The subjects were studied in the recumbent position, wearing light hospital clothing at an ambient room temperature of 20–22 °C. Two catheters were placed intravenously, one in the antecubital vein for infusions and one by a heated-hand vein technique in order to obtain arterialized blood. Each study day consisted of a 4-h basal period (t = 0–240 min) with primed continuous autologous [1-14C]VLDL–TG infusion followed by a 2-h hyperinsulinemic–euglycemic clamp performed for the assessment of insulin sensitivity. The insulin (Actrapid, Novo Nordisk, Hellerup, Denmark) infusion rate was set at 0.6 mU/kg per min and blood glucose was measured every 10 min and clamped at 5.0 mmol/l by a variable 20% glucose infusion. The glucose infusion rate during the final 30 min was considered steady state and used as a measure of insulin sensitivity (M-value). Moreover, a constant 2-h infusion of [9,10-3H]palmitate was performed from T = 120–240 min for the measurement of palmitate turnover and oxidation rates. Steady state blood samples and breath samples were collected during the last 30 min of the basal period (T = 210, 225, and 240 min) for the measurement of concentration and SA of VLDL–TG and palmitate in plasma and 14CO2 in breath. Indirect calorimetry was performed from T = 60–90 min. After the clamp, all catheters were removed, the participants had lunch and when blood glucose had stabilized they were dismissed.

**VLDL–TG tracer preparation**

One week before the metabolic study day, the participants attended the Research Unit after a 12 h overnight fast. An 80 ml blood sample was obtained aseptically to isolate VLDL–TG for ex vivo labeling as previously described (21) with minor modifications. Plasma was separated and then sonicated with 15 μCi of [1-14C]triolein (PerkinElmer, Waltham, MA, USA) at 5 °C for 2 h. The [1-14C]triolein-labeled plasma was transferred to sterile tubes and covered with a saline solution of d = 1.006 g/cm³ and ultracentrifuged (50.3 Ti rotor (37 000 g) or 50.4 Ti rotor (37 000 g), Beckman Instruments, Inc. (Palo Alto, CA, USA)) for 18 h and at 10 °C. The labeled VLDL–TG fraction in the supernatant was obtained with a modified sterile Pasteur pipette, and the solution passed through a Millipore filter with a pore size of 0.20 μm. The VLDL–TG tracer was stored under sterile conditions at 5 °C and a representative sample of the labeled [1-14C]VLDL–TG from all participants was cultured to ensure sterility before autologous infusion.

**Plasma VLDL–TG concentration and SA**

VLDL–TG was separated from ~3 ml plasma by ultracentrifugation as described above. The VLDL fraction in the top layer was obtained by slicing the tube ≈1 cm from the top with a tube slicer (Beckman Instruments, Inc.) and the exact volume was noted. A 300-μl aliquot of the solution was analyzed (Glycerol blanked assay; COBAS c111, Roche) for TG content and the plasma concentration of VLDL–TG was calculated. Scintillation fluid was added to the remaining solution and [3H] and [14C] SA was measured by dual channel liquid scintillation counting to <2% counting error.

**Breath 14CO2-specific activity**

[1-14C]VLDL–TG FA oxidation was calculated from the activity of 14CO2 in expired air. Breath samples were collected in breath bags (IRIS-breath-bags; Wagner Analy- sen Technik, Bremen, Germany) and the air was passed through a solution containing 0.5 ml hyamine hydroxide in 1 M methanol, 2 ml 96% ethanol, and one to two drops of phenolphthalein. A color change occurred when 0.5 mmol CO2 was trapped in the solution, and [14C] activity was measured by liquid scintillation counting to <2% counting error.

**Palmitate turnover and oxidation**

Systemic palmitate turnover and oxidation were measured using the isotope dilution technique with a 2-h constant infusion from T = 120–240 min of [9,10-3H]palmitate (0.3 μCi/min; Department of Clinical Physiology and Nuclear Medicine, Aarhus University Hospital, Denmark) (31). Plasma palmitate concentration and SA were measured at baseline and at T = 150, 160, 170, 180, 195, 210, 225, and 240 min by HPLC using [3H]palmitate as
an internal standard. Steady state SA was verified for each individual at $T=150$, $160$, $170$, and $180$ min. Palmitate flux ($\mu$mol/min) was calculated as $[9,10^{-3}\text{H}]$palmitate infusion rate (d.p.m./min) divided by the steady-state palmitate SA (d.p.m./µmol). Oxidation of plasma palmitate was measured using the slope of the increase in $^3$H$_2$O production rate ($T=120–240$ min). The plasma $[^1$H$_2$O] concentration was determined as described previously (32).

**Table 1** Subject characteristics and anthropometry.

<table>
<thead>
<tr>
<th></th>
<th>C-before</th>
<th>C-after</th>
<th>Tr-before</th>
<th>Tr-after</th>
<th>ANOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>26.1 ± 1.6</td>
<td>79.2 ± 3.3</td>
<td>79.1 ± 3.0</td>
<td>22.1 ± 0.7</td>
<td>75.2 ± 2.8</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>24.0 ± 1.0</td>
<td>24.0 ± 1.0</td>
<td>84 (78–103)</td>
<td>84 (78–103)</td>
<td>0.74</td>
</tr>
<tr>
<td>Waist (cm)</td>
<td>61.0 ± 2.4</td>
<td>59.9 ± 2.1</td>
<td>61.3 ± 2.4</td>
<td>61.5 ± 2.3</td>
<td>0.25</td>
</tr>
<tr>
<td>FFM (kg)</td>
<td>18.2 ± 1.9</td>
<td>19.2 ± 1.6</td>
<td>14.0 ± 4.0</td>
<td>13.7 ± 3.9</td>
<td>0.17</td>
</tr>
<tr>
<td>Fat mass (kg)</td>
<td>6.2 ± 0.5</td>
<td>6.4 ± 0.5</td>
<td>6.4 ± 0.5</td>
<td>4.8 ± 0.5</td>
<td>0.01</td>
</tr>
<tr>
<td>Fat percentage (%)</td>
<td>21.3 ± 1.5</td>
<td>21.9 ± 1.4</td>
<td>18.4 ± 1.5</td>
<td>17.1 ± 1.4</td>
<td>0.01</td>
</tr>
<tr>
<td>Total cholesterol (mM)</td>
<td>3.8 ± 0.2</td>
<td>3.7 ± 0.2</td>
<td>4.1 ± 0.3</td>
<td>4.1 ± 0.3</td>
<td>0.67</td>
</tr>
<tr>
<td>LDL-cholesterol (mM)</td>
<td>1.2 ± 0.1</td>
<td>1.2 ± 0.1</td>
<td>1.2 ± 0.1</td>
<td>1.2 ± 0.1</td>
<td>0.84</td>
</tr>
<tr>
<td>HDL-cholesterol (mM)</td>
<td>2.2 ± 0.2</td>
<td>2.1 ± 0.2</td>
<td>2.5 ± 0.3</td>
<td>2.4 ± 0.3</td>
<td>0.22</td>
</tr>
<tr>
<td>Hemoglobin (mM)</td>
<td>9.2 ± 0.1</td>
<td>9.1 ± 0.1</td>
<td>9.3 ± 0.1</td>
<td>9.0 ± 0.2</td>
<td>0.08</td>
</tr>
</tbody>
</table>

* vs before, † vs control. For age and waist the statistic test was Students $t$-test, for all other parameters RM-ANOVA was used. Data shown as mean ± s.e.m./median (range), * vs before, † vs control. C, $n=9$; Tr, $n=9$; C, control group; Tr, training group; LBM, lean body mass.

**Body composition**

Total body fat mass (FM), leg fat, fat percentage, and fat free mass (FFM) were measured by the dual-energy X-ray absorptiometry (QDR-2000, Hologic, Marlborough, MA, USA) at the end of each metabolic study days.

**Indirect calorimetry**

REE and respiratory exchange ratio (RER) were measured by indirect calorimetry (Deltatrac monitor, Datex Instrumentarium, Helsinki, Finland). Net lipid and glucose oxidation were calculated after correction for protein oxidation (33). Protein oxidation was calculated from urea excretion in urine collected during the basal period.

**Calculations**

VLDL–TG secretion rate ($\mu$mol/min):

$$\text{VLDL–TG infusion rate (d.p.m./min) divided by the steady-state VLDL–TG SA (d.p.m./µmol).}$$

VLDL–TG clearance (ml/min):

$$\text{VLDL–TG secretion rate (C}_{\text{VLDL–TG}}).$$

**VLDL–TG oxidation**

Fractional VLDL–TG oxidation ($\%$) of the infused tracer:

$$\left(\frac{^{14}\text{CO}_2 \text{SA}}{\text{VCO}_2}\right) / (k \times \text{Ar} \times F),$$

where $k$ is the volume of CO$_2$ at 20°C and one atomic pressure (22.4 l/mol), Ar is the fractional acetate carbon recovery factor in breath CO$_2$ (0.56 at rest) (34), and $F$ is the tracer infusion rate.

Total VLDL–TG oxidation rate ($\mu$mol/min):

* Fractional VLDL–TG oxidation $\times$ VLDL–TG secretion rate.

VLDL–TG FA oxidation rate ($\mu$mol/min) was calculated by multiplying VLDL–TG oxidation rate by 3 (three FA per TG molecule). To calculate energy production (kcal/day) from VLDL–TG FA, the rate of VLDL–TG FA oxidation was converted to its weight equivalent using the molecular weight of 282 g/mol of oleic acid and multiplied by the caloric density of 9.1 kcal/g and 1440 min/day.

Plasma FFA oxidation (kcal/24 h):

$$(\text{palmitate ox (µmol/min)} \times 1440 \text{ min} \times 256.42 \text{ g/mol} \times 9.1 \text{ kcal/g})/(0.29 \times 0.8 \times 1 000 000),$$

where 0.29 is the average ratio of palmitate in TG long chain FA, and 0.8 is the recovery factor for $^3$H in $^3$H$_2$O (35), and 256.42 g/mol is the molecular weight of palmitate. The relative contribution of FFA and VLDL–TG FA to oxidation was calculated as the percentage of the total lipid oxidation.
Statistical analyses

Data are presented as mean±s.e.m. or as median (range). Normality of data was checked by QQ-plots, plots of residuals, and equal variance test. Differences at baseline were examined by Student’s t-test or Mann–Whitney’s two-sample test for parametric and non-parametric data respectively. Differences between the effects of exercise and non-exercise regarding kinetic parameters, hormones, substrates, and body composition were examined using two-way ANOVA for repeated measurements; if the ANOVA was significant post hoc analysis was performed (Student–Newman–Keul test). Non-parametric data were logarithmic transformed before ANOVA analysis to ensure normal distribution. Within group changes in the above-mentioned parameters were analyzed using Student’s paired t-test or Wilcoxon’s signed-rank test for parametric and non-parametric data respectively. Since no previous data of the impact of long-term training on VLDL–TG FA measured directly exist, we performed a power analysis based on data showing insulin suppression of VLDL–TG secretion of 36±17% (mean±s.d.) in healthy men (28). We considered half of that reduction, i.e. 18±17%, to be relevant. Thus, with β=0.80 and α=0.05, the sample size was calculated to n=16 (two sample tests) and n=8 (paired t-test). Statistical significance was set at P<0.05.

Results

Subject characteristics and anthropometric data are summarized in Table 1. Total body weight, BMI, FM, and FFM were similar in the two groups. Exercise was associated with a significant decrease in leg fat and in fat percentage.

During the training intervention compliance was 97.0±0.9%, and the participants spent on average 622±27 kcal/exercise bout. VO₂max was not different between the groups at baseline. However, 10 weeks of training improved the maximal oxygen uptake by ≈20% in the Tr group compared with the baseline level (VO₂max (ml/kg per min) C–before: 44.4 (26.0–44.9); C–after: 46.4 (24.6–48.8); Tr–before: 43.5 (35.9–49.6); Tr–after: 51.8 (47.8–56.4), ANOVA, P<0.001). In addition, insulin sensitivity improved in the Tr group compared with C (M-value (mg/kg per min) C–before: 3.5±0.5; C–after: 3.8±0.9, Tr–before: 3.5±0.5; Tr–after: 5.0±0.5, ANOVA, P=0.02). Conversely, REE (REE (kcal/24 h) C–before: 1705±48; C–after: 1696±40; Tr–before: 1716±54; Tr–after: 1817±69, ANOVA, P=0.32) and RER (RER: C–before: 0.84±0.01; C–after: 0.84±0.01; Tr–before: 0.82±0.01; Tr–after: 0.83±0.01, ANOVA, P=0.39) were not significantly different between the groups and were not affected significantly by the intervention.

Substrate concentrations

Basal plasma TG, VLDL–TG, FFA, and insulin concentrations were not significantly different between the groups at baseline, and the concentrations were not
altered significantly during the intervention period in either group (Fig. 1).

VLDL–TG kinetics and oxidation

VLDL–TG secretion and clearance rates are depicted in Fig. 2. No significant differences in VLDL–TG secretion or clearance rates were present at baseline. Moreover, no significant change was noted during the intervention, and no significant difference between the groups occurred during the intervention.

Fractional VLDL–TG oxidation was similar ≈50% (Fig. 3a) in both groups and did not differ significantly between groups during the intervention period (ANOVA, \( P=0.90 \)). Moreover, total VLDL–TG FA oxidation rate (Fig. 3b) was not significantly different between the groups at baseline and remained stable during the intervention. No significant difference was observed between the groups during the intervention (ANOVA, \( P=0.17 \)).

Palmitate turnover and oxidation

Palmitate turnover was not significantly different between the groups at baseline and remained unchanged during the intervention. No significant difference was found between the groups during the intervention (Fig. 4a). A slight, though not significant decrease was noted in the Tr group (post hoc \( P=0.06 \)) but not in the C group (post hoc \( P=0.19 \)). Absolute palmitate oxidation rates were not significantly different between the groups at baseline, and the change in palmitate oxidation was not significantly

![Figure 2](image1.png)

**Figure 2**
VLDL–TG secretion rate (a) and clearance rate (b) before and after 10 weeks' intervention for C and Tr groups respectively. Black bar before, white bar after, mean and s.e.m. error bars. C, \( n=9 \); Tr, \( n=9 \); statistic test, ANOVA.

![Figure 3](image2.png)

**Figure 3**
VLDL–TG oxidation (a) and fractional oxidation (b) before and after 10 weeks' intervention for C and Tr groups respectively. Black bar before, white bar after, mean and s.e.m. error bars. Y-axis in (b) is logarithmic transformed. C, \( n=9 \); Tr, \( n=9 \); statistic test, ANOVA.
different between the groups (Fig. 4b). The fractional palmitate oxidation was not significantly different between the groups at baseline or after the intervention period; however, a small but significant increase was observed in the C group (fractional palmitate oxidation (% of infused tracer) C–before: 13.80±0.01; C–after: 15.90±0.01; Tr–before: 13.00±0.01; Tr–after: 14.10±0.01, ANOVA, P=0.02).

Glucose oxidation

Glucose oxidation was not significantly different between the groups and was not altered during the intervention (glucose oxidation (kcal/24 h) C–before: 29.8±3.4; C–after 23.6±2.4; Tr–before: 24.0±4.5; Tr–after: 30.9±2.0, ANOVA, P=0.68).

Lipid oxidation

There were no significant difference in total lipid oxidation at baseline, nor were there any differences in the relative distribution of plasma FFA oxidation and VLDL–TG FA oxidation, whether this was expressed as total amounts or as percentage of the total lipid oxidation (Table 2). Also, the intervention did not result in any significant changes in the contribution of the different lipid sources for oxidation in either group. The equivalent energy production attributed to VLDL–TG FA oxidation (Table 2) resulted in comparable relative contributions of basal VLDL–TG FA oxidation with REE of ~15% before and after intervention in both groups (ANOVA, P=0.32).

Discussion

In this study, we examined the effect of a long-term training program on VLDL–TG FA and palmitate kinetics, and its relationship with whole-body lipid and glucose metabolism. Despite the expected improvement in VO₂max and whole-body insulin sensitivity, there was no persistent effect of 10 weeks of training on VLDL–TG FA secretion, clearance, or oxidation rates. Additionally, neither REE, RER, nor palmitate turnover or oxidation

Table 2  Distribution of total lipid oxidation between FFA, VLDL–TG FA, and the residual lipid oxidation. For one participant in Tr it was not possible to measure palmitate oxidation due to lack of material. Data shown as mean ± s.e.m./median (range).

<table>
<thead>
<tr>
<th></th>
<th>C–before</th>
<th>C–after</th>
<th>Tr–before</th>
<th>Tr–after</th>
<th>ANOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total lipid ox (kcal/h)</td>
<td>27 (10–37)</td>
<td>24 (11–35)</td>
<td>28 (24–52)</td>
<td>38 (22–59)</td>
<td>0.18</td>
</tr>
<tr>
<td>FFA ox (kcal/h)</td>
<td>13.8±1.7</td>
<td>13.2±1.4</td>
<td>13.8±2.8</td>
<td>13.3±1.6</td>
<td>0.88</td>
</tr>
<tr>
<td>FFA ox (% of total lipid ox)</td>
<td>50±7</td>
<td>57±9</td>
<td>45±4</td>
<td>44±6</td>
<td>0.64</td>
</tr>
<tr>
<td>VLDL–TG FA ox (kcal/h)</td>
<td>3.4±0.4</td>
<td>4.0±0.6</td>
<td>3.4±0.7</td>
<td>4.0±0.8</td>
<td>0.29</td>
</tr>
<tr>
<td>VLDL–TG FA ox (% of total lipid ox)</td>
<td>37±7</td>
<td>41±8</td>
<td>36±6</td>
<td>34±8</td>
<td>0.13</td>
</tr>
<tr>
<td>Residual lipid ox (kcal/h)</td>
<td>2.5±3.8</td>
<td>−0.8±4.1</td>
<td>6.9±2.4</td>
<td>4.9±4.5</td>
<td>0.25</td>
</tr>
</tbody>
</table>

C, n=9; Tr, n=7; Ox, oxidation; C, control group; Tr, training group; FFA, free fatty acids; VLDL–TG, very LDL triglyceride; FA, fatty acids.
were significantly altered by training as compared with control subjects.

This is the first study to perform combined direct measurements of whole-body VLDL–TG and palmitate kinetics and oxidation before and after long-term supervised endurance training in healthy sedentary men. Most previous studies have examined VLDL–TG kinetics in relation to a single bout of exercise and reported increased VLDL–TG clearance of short duration (1 day) (9, 10, 12, 22). In order to investigate the long-term effects of training while at the same time avoiding interference of any residual effects induced by acute exercise, this study was designed so that the metabolic study day was placed 60–72 h after the last exercise bout. This time frame was chosen because it has been shown in many studies that measurable improvements in both insulin sensitivity to glucose metabolism and in physical performance capacity (VO2max) persists after this time, whereas improvement in TG concentrations do not change. Thus, the question arises whether persistent changes in VLDL–TG kinetics, as opposed to VLDL–TG concentration measurements, are also present at this prolonged time point. Although we found a persistent increase in whole-body insulin sensitivity 60–72 h after the last exercise bout, we could not demonstrate a concomitant change in basal hepatic VLDL–TG secretion or palmitate turnover. To our knowledge, only one other study has investigated long-term training effects on VLDL–TG kinetics in healthy non-obese men 48 h after the last exercise bout (19), using infusion of a glycerol precursor followed by mathematical modeling of the plasma tracer data. The authors performed an endurance training protocol for 8 weeks in healthy men, which showed no significant changes in body weight or plasma levels of FFA and TG. Interestingly, however, 48 h after the last exercise bout they did observe an increase in VLDL–TG secretion but no difference in clearance rates (19). We speculate that this finding could be a temporary state in the metabolic adaptation (i.e. increased secretion) that may occur after the immediate TG redistribution period in healthy lean men. However, methodological aspects may also have influenced the results. Finally, with this indirect approach it is not possible to calculate substrate oxidation, which is pivotal in all exercise studies (19).

Assessment of VLDL–TG FA oxidation has previously proven to be methodologically challenging. However, in this study we used a novel and validated method that allows direct measurements of VLDL–TG FA oxidation (21). VLDL–TG contributes significantly to energy expenditure (EE) at rest (10–15%) (23, 24), but the effective amount oxidized remains unaltered during acute aerobic exercise in healthy lean subjects (22). In this study, we extend these findings to include an unchanged VLDL–TG FA oxidation following long-term training in healthy men. Thus, it appears that in healthy adults any effects on VLDL–TG metabolism are temporary and disappear within a few hours after an exercise bout. It cannot be excluded, however, that other training modalities such as resistance exercise, more prolonged training periods, or exercise of higher intensity, could have yielded a different outcome. Still, the training program used did improve both physical performance and insulin sensitivity. Interestingly, some studies have shown that the combination of endurance and resistance exercise is more potent in lowering the concentrations of TG, LDL-cholesterol, and apoB-100 compared with either exercise form separately (36, 37). This could indicate that resistance exercise might possess a different potential in the modulation of VLDL–TG kinetics. In this study, we find that resting lipid oxidation originating from other sources than plasma FFA and VLDL–TG FA, i.e. i.m. TG, are negligible (Table 2), which is consistent with studies done in obese individuals at rest (38) and during very-low intensity exercise (39).

Only few studies have been able to modulate postabsorptive VLDL–TG oxidation. Consumption of a high-fat diet showed increased leg VLDL–TG net clearance during exercise compared with a high-carbohydrate diet (40, 41); this finding was unaffected by VLDL–TG concentration and training program (40). However, measurement of leg a-v differences, which was used in these studies, does not allow differentiation between increased storage of VLDL–TG in leg fat vs muscle tissue or to calculate oxidation, which therefore could explain some of the observed difference in leg clearance. Conversely, in a previous study, we reported that growth hormone infusion did not change VLDL oxidation in healthy adults although FFA levels and whole-body lipid oxidation were increased (42, 43).

The previously mentioned acute kinetic changes during exercise and in the early recovery period (22) could indicate that a redistribution of TG and VLDL–TG takes place during that period, replenishing TG depots in, for example, muscle and liver during the recovery period, thereby potentially improving the ability to meet energy needs. The data from this study lends indirect support to the theory of a temporary acute TG FA redistribution, as the hepatic secretion rate was unchanged 60–72 h after the last exercise bout, despite improved physical performance and insulin sensitivity. The lack of a persistent effect of endurance training on VLDL–TG kinetics and
Clinical Study

B Nelleman and others

VLDL–TG kinetics and effects of training

171:5

611

European Journal of Endocrinology

change VLDL–TG secretion, clearance and oxidation or dietary intake during the study period. This observation can explain the reversion of the increased clearance seen on the day after exercise, and supports the concept of a post-exercise redistribution of TG FA. Moreover, LPL activity is reduced in skeletal muscle and up-regulated in adipose tissue when athletes detrain (46), again indicating a differentiation in lipid distribution (i.e. deposition vs oxidation) depending on the time elapsed since the last exercise bout.

There are limitations to our study. First, due to the small sample size a type 2 error cannot be excluded; yet tracer studies in combination with supervised long-term training are demanding and therefore limits the ability to recruit large numbers of participants. On the other hand, a sufficient number of subjects were included to detect significant differences in VO2max and insulin sensitivity. Second, there is a possibility of tracer recycling. However, in constant-infusion studies recycling of labeled VLDL–TG compose a minor part of steady state VLDL–TG SA, which is used for calculation of hepatic VLDL–TG secretion (47). Third, as mentioned, we cannot extend our findings to other forms of exercise, e.g. resistance exercise. Also, we do not have measurements of daily activity, and it is possible that our participants have reached a chronic high low-intensity exercise level with a near-maximum VLDL–TG metabolism. Therefore, we cannot extend the present findings to subjects with minimal daily activity. Fourth, it is possible that the result would have been different if the population investigated were either female, obese, had increased intrahepatic fat content, increased basal VLDL–TG secretion, or were insulin resistant. Fifth, no registration of food consumption was done in this study. However, both diet composition and calorie consumption can affect fasting TG synthesis. Consumption of a carbohydrate enriched diet results in a greater amount of glucose-derived FA TG without altering overall TG production, unless a hypercaloric diet is ingested (48). In addition, day-to-day variability of fasting VLDL–TG secretion rate in healthy volunteers (similar to those in our study), who were dietary controlled the day before the kinetic measurements, has previously been assessed to be around 15% (49), i.e. similar to our findings. Although we did not record food consumption in this study, we believe that given the constant body weight before and after the intervention periods lends some confidence to a stable dietary intake during the study period.

In summary, 10 weeks of endurance training did not change VLDL–TG secretion, clearance and oxidation or palmitate turnover and oxidation rate despite improved insulin sensitivity and physical fitness. We conclude that the present persistent improvements in maximal oxygen uptake (≈20%) and insulin sensitivity (≈60%) do not induce persistent changes in VLDL–TG metabolism 60–72 h after the last exercise bout. Probably, endurance exercise must be performed frequently to maintain a favorable impact on VLDL–TG metabolism.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

The study has been financially supported by the World Anti-Doping Agency, The Novo Nordic Foundation, and The Danish Medical Research Council.

Author contribution statement

B Nelleman designed the study, conducted the study, researched the data, and wrote the manuscript. B Christensen designed the study, contributed to the discussion, and reviewed the manuscript. K Vissing designed the exercise training protocol, contributed to the discussion, and reviewed the manuscript. L Thams, P Sieljacks, and M S Larsen conducted the study, and reviewed the manuscript. J O L Jørgensen contributed to the discussion, and reviewed the manuscript. S Nielsen researched the data, contributed to the discussion, and reviewed the manuscript.

Acknowledgements

The authors thank Lone Kvist, Susanne Sørensen, Elsebeth Hornemann, Hanne F Petersen, Kirsten Nyborg Rasmussen, and Eva Schriver for excellent technical assistance.

References


